GlassScriptPhysician profile
Mehul R Shah
NPI 1538196043
$6,196.01
in general payments reported to CMS, 2019-2025
38 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $73.26 · 2021: $297 · 2022: $849 · 2023: $1,293 · 2024: $1,539 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,832 · Education: $12.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,832.12 |
| Education | $12.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $715.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $668.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $665.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Baxter Healthcare | $407.00 | 2023-2024 | Peri-Strips Dry |
| Bayer Healthcare Pharmaceuticals INC. | $393.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $381.49 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $366.13 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $365.11 | 2019-2025 | |
| Abbott Laboratories | $259.53 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.16 | 2019-2023 | |
| Amgen INC. | $175.46 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Boston Scientific Corporation | $174.13 | 2022-2023 | Watchman Access System |
| Seqirus USA INC | $158.49 | 2023-2025 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Smith+Nephew, INC. | $147.19 | 2022 | |
| Aroa Biosurgery Incorporated | $140.15 | 2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.